These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 2159188)

  • 1. Gynecologic Oncology Group experience with ifosfamide.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gynecologic Oncology Group studies with ifosfamide.
    Sutton GP; Blessing JA; Manetta A; Homesley H; McGuire W
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):31-4. PubMed ID: 1485172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Adcock L; Webster KD; DeEulis T
    Invest New Drugs; 1989 Nov; 7(4):341-3. PubMed ID: 2513286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; Malfetano JH
    Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of ifosfamide in cervical cancer.
    Meanwell CA; Mould JJ; Blackledge G; Lawton FG; Stuart NS; Kavanagh J; Latief TN; Spooner D; Chetiyawardana AD
    Cancer Treat Rep; 1986 Jun; 70(6):727-30. PubMed ID: 3089596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
    Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Barrett RJ; McGehee R
    Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
    Kredentser DC
    Gynecol Oncol; 1991 Nov; 43(2):145-8. PubMed ID: 1743556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
    Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer.
    Murad AM; Triginelli SA; Ribalta JC
    J Clin Oncol; 1994 Jan; 12(1):55-9. PubMed ID: 7505808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
    Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
    Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
    Araujo CE; Cervellino JC; Pirisi C; Pannunzio O; Callegari J
    J Surg Oncol; 1991 Mar; 46(3):198-202. PubMed ID: 1901372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.